CD96 as a Potential Diagnostic Biomarker and  New  Target for Skin Cutaneous Melanoma

Zhou, Wangying; Cai, Xiao-bin; Liu, Feng

doi:10.1155/2022/6409376

Cited by 2 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies demonstrated the poor prognosis of low SOX17 protein expression in ESCC patients, and up- regulation of SOX17 in ESCC cells led to reduced lesion formation, decreased cell activity, and metastasis [ 21 ]. Increasing findings showed that CD96 served for the diagnosis and treatment of patients with skin cutaneous melanoma [ 22 ], glioma [ 23 ], and cervical cancer [ 24 ]. In the validation part of this study, we confirmed the impact of CD96 down-regulated expression on KYSE-150 and TE-1 cells in cell cycle, reduced proliferation, and increased apoptosis.…”

Section: Discussionmentioning

confidence: 99%

A demonstration based on multi-omics transcriptome sequencing data revealed disulfidptosis heterogeneity within the tumor microenvironment of esophageal squamous cell carcinoma

Liu¹,

Yuan²,

Liu³

et al. 2023

Discov Onc

View full text Add to dashboard Cite

Background It is of great concern to identify prognostic signatures for the prediction and prediction of esophageal squamous cell carcinoma (ESCC), which is the lethal pathological type of malignancy. Method Bulk RNA sequencing and scRNA-seq data were retrieved from GSE53624, GSE53622, and GSE188900. Disulfidptosis-related differentially expressed genes (DEGs) were identified between disulfidptosis-high score and disulfidptosis-low score groups. Functional annotation of DEGs were analyzed by Gene Ontology (GO). Consistent clustering and co-expression modules were analyzed, and then constructed a risk score model via multivariate Cox regression analysis. Immune infiltration and immunotherapy response analyses were conducted based on risk score. qRT-PCR, colony formation assay, and flow cytometry analysis were conducted in KYSE-150 and TE-1 cell lines. Results Seven genes (CD96, CXCL13, IL2RG, LY96, TPK1, ACAP1, and SOX17) were selected as marker genes. CD96 and SOX17 are independent prognostic signatures for ESCC patients, with a significant correlation with infiltrated immune cells. ESCC patients had worse response to nivolumab in the high-risk group. Through cellular experiments, we found that CD96 expression was associated with apoptosis and cell cycle ESCC cells. Conclusion In a word, the risk score based on disulfidptosis is associated with prognosis and the immune microenvironment, which may direct immunotherapy of ESCC. The key gene of risk score, namely CD96, plays a role in proliferation and apoptosis in ESCC. We offer an insight into the exploration of the genomic etiology of ESCC for its clinical management.

show abstract

Section: Discussionmentioning

confidence: 99%

A demonstration based on multi-omics transcriptome sequencing data revealed disulfidptosis heterogeneity within the tumor microenvironment of esophageal squamous cell carcinoma

Liu¹,

Yuan²,

Liu³

et al. 2023

Discov Onc

View full text Add to dashboard Cite

show abstract

“…The expression of CD96 is upregulated in melanoma [ 204 ], and the protein is also found to be expressed by NK cells and CD8 + T cells [ 182 , 184 ], capable of further tuning the activity of these cells [ 181 , 182 , 205 , 206 ]. CD96 prevents IL-12-induced CD8 + T-cell-dependent anti-tumour effects, especially by downregulating cytokine secretion [ 181 ].…”

Section: The Role Of Cd155 In the Melanoma Microenvironment And Its P...mentioning

confidence: 99%

Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling

Wu,

Park,

Jakobsson

et al. 2024

Cancers

View full text Add to dashboard Cite

Melanoma is commonly diagnosed in a younger population than most other solid malignancies and, in Australia and most of the world, is the leading cause of skin-cancer-related death. Melanoma is a cancer type with high immunogenicity; thus, immunotherapies are used as first-line treatment for advanced melanoma patients. Although immunotherapies are working well, not all the patients are benefitting from them. A lack of a comprehensive understanding of immune regulation in the melanoma tumour microenvironment is a major challenge of patient stratification. Overexpression of CD155 has been reported as a key factor in melanoma immune regulation for the development of therapy resistance. A more thorough understanding of the actions of current immunotherapy strategies, their effects on immune cell subsets, and the roles that CD155 plays are essential for a rational design of novel targets of anti-cancer immunotherapies. In this review, we comprehensively discuss current anti-melanoma immunotherapy strategies and the immune response contribution of different cell lineages, including tumour endothelial cells, myeloid-derived suppressor cells, cytotoxic T cells, cancer-associated fibroblast, and nature killer cells. Finally, we explore the impact of CD155 and its receptors DNAM-1, TIGIT, and CD96 on immune cells, especially in the context of the melanoma tumour microenvironment and anti-cancer immunotherapies.

show abstract

CD96 as a Potential Diagnostic Biomarker and New Target for Skin Cutaneous Melanoma

Cited by 2 publications

References 17 publications

A demonstration based on multi-omics transcriptome sequencing data revealed disulfidptosis heterogeneity within the tumor microenvironment of esophageal squamous cell carcinoma

A demonstration based on multi-omics transcriptome sequencing data revealed disulfidptosis heterogeneity within the tumor microenvironment of esophageal squamous cell carcinoma

Immune Regulation and Immune Therapy in Melanoma: Review with Emphasis on CD155 Signalling

Contact Info

Product

Resources

About